- Home
- GIFT vs BLRX Comparison
GIFT vs BLRX Comparison
Compare GIFT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIFT
- BLRX
- Stock Information
- Founded
- GIFT 1999
- BLRX 2003
- Country
- GIFT United States
- BLRX Israel
- Employees
- GIFT N/A
- BLRX N/A
- Industry
- GIFT Catalog/Specialty Distribution
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GIFT Consumer Discretionary
- BLRX Health Care
- Exchange
- GIFT Nasdaq
- BLRX Nasdaq
- Market Cap
- GIFT 40.4M
- BLRX 15.3M
- IPO Year
- GIFT N/A
- BLRX 2011
- Fundamental
- Price
- GIFT $1.14
- BLRX $4.52
- Analyst Decision
- GIFT Strong Buy
- BLRX Strong Buy
- Analyst Count
- GIFT 1
- BLRX 2
- Target Price
- GIFT $4.00
- BLRX $19.00
- AVG Volume (30 Days)
- GIFT 61.6K
- BLRX 64.3K
- Earning Date
- GIFT 08-15-2025
- BLRX 08-14-2025
- Dividend Yield
- GIFT N/A
- BLRX N/A
- EPS Growth
- GIFT N/A
- BLRX N/A
- EPS
- GIFT N/A
- BLRX N/A
- Revenue
- GIFT $89,689,155.00
- BLRX $22,340,000.00
- Revenue This Year
- GIFT $12.22
- BLRX N/A
- Revenue Next Year
- GIFT $13.86
- BLRX N/A
- P/E Ratio
- GIFT N/A
- BLRX N/A
- Revenue Growth
- GIFT 6.13
- BLRX 91.68
- 52 Week Low
- GIFT $0.50
- BLRX $2.30
- 52 Week High
- GIFT $4.22
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- GIFT N/A
- BLRX 50.14
- Support Level
- GIFT N/A
- BLRX $4.40
- Resistance Level
- GIFT N/A
- BLRX $5.06
- Average True Range (ATR)
- GIFT 0.00
- BLRX 0.34
- MACD
- GIFT 0.00
- BLRX -0.02
- Stochastic Oscillator
- GIFT 0.00
- BLRX 46.53
About GIFT RDE Inc. Common Stock
Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.